Oncolytics Biotech Inc T.ONC

New Press Release - Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

Pelareorep induced prominent expansion of pre-existing Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumorData highlights the association between the expansion of existing TILs in the blood and decreased tumor sizeResults affirm pelareorep's role as an immunotherapySAN...read article.

[Noteable]

December 07, 2023 - Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics, commented, "A review of the AWARE-1 study translational data presented at this year's SABCS and previous scientific conferences demonstrates that pelareorep treatment, especially in combination with atezolizumab, results in: an increase in CelTIL score, which correlates with improved clinical

[Noteable]

What is accelerated approval? The Accelerated Approval Program is a drug development pathway that offers an approval based on a “surrogate” marker in a clinical trial. A surrogate marker is a biomarker or clinical marker that can be measured at an earlier point in a trial than the type of endpoints that may be used in a traditional approval. For example, a company might submit an application

[canadafan]

In simple terms, Onc has clear proven veryfied " biomarker", data.  Meaning mutiple very early oppotunities to know if the Pea treatment would work for each individual, prior to a long treatment cycle. They have positive efficacy data with 3 of the 4 Goblet trials with Roche. All that is left to do is sign a deal. Why so long? Not one person posting on here can know that

[itntdf]

LOS ANGELES, Sept. 29, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading nonprofit in the fight against pancreatic cancer, is thrilled that the U.S. House of Representatives approved an amendment to the Defense Appropriations Bill, increasing funding for the dedicated Pancreatic Cancer Research Program at the Department of Defense (DoD) from $15 to $20 million for the

[Quentin30]

NO NO NO Canaduh. Reread the new release "We believe that analysis of TIL clone expansion could become a helpful precision tool to provide an early indication of treatment response and serve as a potential guide to patient care with pelareorep. " We "believe" is NOT proof. ONCY never states IS, for years all we have is "could", "might", "suggests"

[Azzak34]

Haha silly silly Quentin! All that talk of biomarkers amd now guess what?!  Hey weren't you the one complaining about ad hominem attacks? Seems like once again lil Quento does what he criticizes other people of.  Oh it's the same way every drug company in the works days "could" and "may", it's built in disclaimer and I know you're stupid but you know

[venture009]

Quentin, the market action confirms your interpretation of the release.  Anytime you have the chief medical officer saying "we believe "  or "leads us to believe " after a statement, you have to  "believe" they need more studies. Now that's a news flash.  Everything this company does scientifically is done by a 3rd party so no telling what the

[Azzak34]

Haha another Dummy. Have a read stupid.  https://www.tecentriq-hcp.com/sclc.html

[Noteable]

We believe that analysis of TIL clone expansion could become a helpful precision tool to provide an early indication of treatment response and serve as a potential guide to patient care with pelareorep. " ... is a very powerful aspiration statement that may come to fruition sooner now than later.

[Noteable]

These findings confirm that pelareorep remodels the tumor microenvironment and stimulates tumor-directed immune responses, effects we believe are driven by the introduction of pelareorep's double-stranded RNA into cancer cells." Dr. Heineman concluded, "Results from multiple prior studies lead us to believe that pelareorep has the potential to fill very important treatment gaps for